NATCO Pharma LimitedNSE: NATCOPHARM

Press Release Aug 17 2022

· Issued by NATCO Pharma Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

NATCO Pharma Limited has announced the tentative approval of its ANDA for Trabectedin, a generic version of Yondelis, by the U.S. Food and Drug Administration. This approval pertains to the one milligram per vial presentation of the drug.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

NATCO Pharma Limited on 6ix

Earlier from NATCO Pharma

Later from NATCO Pharma

All NATCO Pharma news releases